Status:

NOT_YET_RECRUITING

A Study to Evaluate the Effect of KarXT on Urological Safety

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Male and Female participants (age 18 to 65 years of age, with a primary diagnosis of schizophrenia based on psychiatric evaluation (DSM-5) and confirmed by MINI (v 7.0.2).
  • Participants must have a PANSS total score ≤ 80 and CGI-S score ≤ 4, at screening and baseline, and a BMI ≥18 and ≤ 40 kg/m2.
  • Participants must be willing and able to discontinue all antipsychotic medications prior to the baseline visit and be willing and able to comply with protocol requirements.
  • Exclusion Criteria
  • Participants with newly diagnosed schizophrenia, any other DSM-5 disorder diagnosed within the past 12 months, alcohol or drug use disorder within the past 12 months, history/presence of clinically significant disease or disorder that would jeopardize participant safety or validity of study results.
  • Participants at risk for suicidal behavior, as well as individuals who are pregnant or breastfeeding, will be excluded from the study.
  • Other protocol-defined Inclusion/Exclusion criteria apply

Exclusion

    Key Trial Info

    Start Date :

    January 21 2026

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 30 2027

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT07221877

    Start Date

    January 21 2026

    End Date

    December 30 2027

    Last Update

    October 28 2025

    Active Locations (16)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (16 locations)

    1

    Local Institution - 0017

    Little Rock, Arkansas, United States, 72204

    2

    Local Institution - 0007

    Bellflower, California, United States, 90706

    3

    Local Institution - 0009

    Culver City, California, United States, 90230

    4

    Local Institution - 0006

    Los Alamitos, California, United States, 90720

    A Study to Evaluate the Effect of KarXT on Urological Safety | DecenTrialz